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Background: To evaluate the evolution of fecal calprotectin levels in patients with ulcerative 
colitis (UC) under maintenance treatment with infliximab. 
Methods: 113 UC patients, 83 from Belgium and 30 from Norway, in clinical remission 
under a stable 5  mg/kgQ8W infliximab therapy were followed-up over 1 year. Faecal 
calprotectin was measured monthly. Clinical and biochemical examination was performed at 
each infusion. Sigmoidoscopies were performed at inclusion and after 1 year, or earlier if 
patients dropped out of the study due to flare. “Active disease” was defined by the clinical 
Mayo score during the study or by an endoscopic score of ≥2 at week 52. “Deep remission” 
was defined by a normal endoscopy at the start of the study and at week 52 associated with 
clinical mayo scores at all times <3. 
Results: After 1 year, 83 (73.5%) of 113 patients remained in clinical remission and 
continued the study till week 52. Discontinuation was observed in 28 patients: 7 (5.8%) due to 
flare, 5 (4.4%) due to safety issues (2 hypersensitivity reaction, 1 joint pain, 1 adrenal tumor, 
1 polyneuropathy) and 16 due to withdrawal of consent. “Active disease” was observed in 
13/113 (11%) patients and “deep remission” in 30/113 (26.5%) patients. In patients in deep 
remission median calprotectin levels were less than 50  mg/kg at all measured time points. 
Patients who flared had significantly higher calprotectin levels at the moment of flare (median 
calprotectin levels of 477  mg/kg). Significant increase was already observed 3 months 
before flare. Further ROC analysis (flare vs deep remission at last evaluation) suggested that a 
calprotectin level >300  mg/kg showed a reasonable sensitivity (58.3%) and high specificity 
(93.3%) to model flare and a calprotectin level <50  mg/kg to model deep remission 
(sensitivity 83.3% and specificity 83.3%). Two consecutive calprotectin measurements of 
>300  mg/kg predicted a flare with a sensitivity of 61.5% and specificity of 100% (remission 
vs flare). 
Conclusions: In UC patients under infliximab maintenance therapy calprotectin levels highly 
correlate with disease activity. Deep remission is associated with very low levels. A flare is 
associated with high levels (median >300  mg/kg). Two consecutive calprotectin levels of 
>300  mg/kg predict a flare. 
 
